ImmuneOncia Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	715.75	654.54	110	7,733	35.95	2.5
Other Revenue	-	-	-	-	0	-
Revenue	715.75	654.54	110	7,733	35.95	2.5
Revenue Growth (YoY)	550.68%	495.04%	-98.58%	21413.29%	1337.90%	66.67%
Cost of Revenue	12.56	11.12	17.09	17.85	7.8	5.36
Gross Profit	703.19	643.42	92.91	7,716	28.15	-2.86
Selling, General & Admin	7,799	4,964	5,038	7,662	5,075	2,958
Research & Development	13,159	7,386	6,034	14,243	6,012	8,914
Amortization of Goodwill & Intangibles	574.99	574.44	565.53	567.15	567.03	565.3
Other Operating Expenses	36.44	19.64	19.55	15.15	12.63	3.3
Operating Expenses	21,834	13,242	11,890	22,789	11,924	12,638
Operating Income	-21,131	-12,599	-11,797	-15,073	-11,896	-12,641
Interest Expense	-5.53	-6.93	-3.13	-	-	-
Interest & Investment Income	628.89	690.31	769.15	-	-	-
Currency Exchange Gain (Loss)	-23.27	-49.41	9.51	75.7	192.43	21.03
Other Non Operating Income (Expenses)	11.29	6,278	19,886	11,507	-48,783	-6,528
EBT Excluding Unusual Items	-20,520	-5,686	8,865	-3,490	-60,487	-19,148
Gain (Loss) on Sale of Assets	-0.55	-0.55	-0.77	-1.38	-3.18	-9.39
Pretax Income	-20,520	-5,687	8,864	-3,492	-60,490	-19,158
Net Income	-20,520	-5,687	8,864	-3,492	-60,490	-19,158
Net Income to Common	-20,520	-5,687	8,864	-3,492	-60,490	-19,158
Shares Outstanding (Basic)	67	56	52	52	46	5
Shares Outstanding (Diluted)	67	56	52	52	46	5
Shares Change (YoY)	27.73%	7.35%	0.64%	12.17%	904.47%	-0.01%
EPS (Basic)	-306.31	-101.00	169.00	-67.00	-1302.00	-4142.00
EPS (Diluted)	-306.31	-101.00	169.00	-67.00	-1302.00	-4142.00
Free Cash Flow	-18,632	-14,750	-8,766	-15,337	-2,078	-10,322
Free Cash Flow Per Share	-278.12	-261.96	-167.13	-294.29	-44.72	-2231.70
Gross Margin	98.25%	98.30%	84.47%	99.77%	78.31%	-114.52%
Operating Margin	-2952.31%	-1924.80%	-10724.51%	-194.91%	-33093.66%	-505642.37%
Profit Margin	-2866.97%	-868.86%	8058.20%	-45.15%	-168272.99%	-766313.44%
Free Cash Flow Margin	-2603.11%	-2253.53%	-7968.93%	-198.32%	-5779.96%	-412888.34%
EBITDA	-20,212	-11,547	-10,766	-13,992	-10,870	-11,684
EBITDA Margin	-	-	-	-180.93%	-	-
D&A For EBITDA	919.5	1,051	1,031	1,081	1,026	956.83
EBIT	-21,131	-12,599	-11,797	-15,073	-11,896	-12,641
EBIT Margin	-	-	-	-194.91%	-	-
Advertising Expenses	-	1	1	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.